Engineered Cells Expressing Multiple Immunomodulators and Uses Thereof

Abstract

This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (IL-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals.

1 - 20 . (canceled) 
     
     
         21 . An adenoviral vector for conditionally expressing proteins, the vector comprising a polynucleotide encoding an ecdysone gene switch, wherein said polynucleotide comprises
 (1) polynucleotide sequence comprising a first transcription factor sequence and a second transcription factor sequence under the control of a promoter, wherein the proteins encoded by the first transcription factor sequence and second transcription factor sequence interact to form a ligand-dependent transcription factor complex,   wherein the first transcription factor sequence comprises a nucleic acid encoding a VP-16 transactivation domain and a retinoic acid-X-receptor (RXR) polypeptide,   wherein the RXR polypeptide is a genetically engineered chimera comprising vertebrate RXR and invertebrate RXR domains,   wherein said vertebrate RXR ligand binding domain is a human RXR ligand binding domain,   wherein the second transcription factor sequence comprises a nucleic acid encoding a GAL-4 DNA binding domain and an ecdysone receptor protein,   wherein said ecdysone receptor ligand binding domain is derived from a  Choristoneura fumiferna  ecdysone receptor ligand binding domain, and   wherein said  Choristoneura fumiferna  ecdysone receptor ligand binding domain further comprises a genetically engineered substitution mutation compared to the naturally occurring  Choristoneura fumiferna  ecdysone receptor ligand binding domain from which it was derived;   (2) a polynucleotide encoding a polypeptide at least 90% identical to IL12; and,   (3) a polynucleotide encoding a polypeptide at least 90% identical to IL-21; wherein at least one polynucleotide of (2) or (3) are linked to a promoter capable of being activated by said ligand dependent transcription factor complex.   
     
     
         22 . A pharmaceutical composition comprising the adenoviral vector of  claim 21 . 
     
     
         23 . A kit comprising the adenoviral vector of  claim 21 . 
     
     
         24 . The adenoviral vector of  claim 21 , wherein the polypeptide at least 90% identical to IL-12 is at least 95% identical to IL-12, and wherein the polypeptide at least 90% identical to IL-21 is at least 95% identical to IL-21. 
     
     
         25 . The adenoviral vector of  claim 21 , wherein the polypeptide at least 90% identical to IL-12 is at least 99% identical to IL-12, and wherein the polypeptide at least 90% identical to IL-21 is at least 99% identical to IL-21. 
     
     
         26 . The adenoviral vector of  claim 21 , wherein the polynucleotide sequence comprising a first transcription factor sequence and a second transcription factor sequence is under the control of a Ubiquitin C promoter. 
     
     
         27 . The adenoviral vector of  claim 21 , wherein the RXR polypeptide comprises human RXR and locust RXR domains. 
     
     
         28 . The adenoviral vector of  claim 21 , wherein the nucleic acid encoding a GAL-4 DNA binding domain and an ecdysone receptor protein encodes amino acids 1-147 of yeast Gal4 and the DEF domains of the ecdysone receptor from  Choristoneura fumiferna.    
     
     
         29 . The adenoviral vector of  claim 21 , wherein the first transcription factor sequence and the second transcription factor sequence are separated by an internal ribosome entry site. 
     
     
         30 . The adenoviral vector of  claim 29 , wherein the internal ribosome entry site is from EMCV.